"Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
Von Moos
Roger
R
Cathomas
Richard
R
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004337:Drug Carriers / Q000008:administration & dosage* / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology; D062787:Drug Overdose; D005533:Foot Dermatoses / Q000139:chemically induced*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D010292:Paresthesia / Q000139:chemically induced; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects*; D013577:Syndrome
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin